Qiagen NV (WBO:QGE2)
€ 40.8 -0.54 (-1.31%) Market Cap: 9.01 Bil Enterprise Value: 9.48 Bil PE Ratio: 137.61 PB Ratio: 2.86 GF Score: 87/100

Qiagen NV at Goldman Sachs MedTech Conference (Virtual) Transcript

Sep 08, 2021 / 12:50PM GMT
Release Date Price: €48.91 (-0.61%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good afternoon, everyone. I'm Matt Sykes, the senior life sciences, tools and diagnostics analyst at Goldman Sachs. I have the pleasure of welcoming QIAGEN to the conference today. We have, presenting from QIAGEN, Roland Sackers, the Chief Financial Officer. Roland, thanks so much for joining us. Appreciate you coming here.

Roland Sackers
QIAGEN N.V. - CFO, MD & Member of Management Board

Thank you, Matt. Thanks for having us.

Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

I thought maybe we'd start out and let you just set the stage for a few minutes, talk about your most recent quarter, some of the changes you made to guidance and what your expectations are for the rest of the year.

Roland Sackers
QIAGEN N.V. - CFO, MD & Member of Management Board

Sure. Yes, as you know, I would say the start of the year for us were actually quite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot